# Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer

> **NCT00500760** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 153 (actual)

## Conditions studied

- Head and Neck Cancer
- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Cisplatin
- **RADIATION:** Standard Fractionation Radiotherapy
- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT00500760
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-01
- **Primary completion:** 2011-03-29
- **Final completion:** 2011-04-26
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00500760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00500760, "Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00500760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*